Effect of Palmitoleic Acid on C-reactive Protein
Chronic Inflammation, Overweight

About this trial
This is an interventional treatment trial for Chronic Inflammation focused on measuring palmitoleic acid, monounsaturated fatty acid, chronic inflammation
Eligibility Criteria
Inclusion Criteria:
- Subject will be free-living, middle-aged to older men and women between ages 18-80 years with BMIs between 20.0-40.0, and CRP greater than or equal to 2.0 mg/L
- Generally healthy adults
- Understand protocol and comply to take supplements during the trial
- Ability to understand English
- Be able to report to clinical research center, fasting, at least 3 times
- Women who are of childbearing potential should be on birth control (one method is acceptable)
Exclusion Criteria:
- BMI higher than 40.0
- Taking anti-hyperlipidemia medications (including statins)
- Taking anti-diabetic medications
- Auto-immune disease
- Documented cognitive impairment
- Unable to draw blood from veins
- Alcohol or other drug dependency
- Are currently breastfeeding, or pregnant, or plan to become pregnant
- Have experienced a significant weight change of 10%, or more, of body weight in previous 3 months
- If on hormone therapy, no change during study
- Chronic use of NSAIDs
- Decreased QOL due to pathology, such as cancer, genetic diseases, Rx side effects, or injury
- Taking fish oil, within 8 weeks of enrollment
- Taking Seabuckthorn supplements
- Taking sterols or fat blockers
- Fish allergies
Sites / Locations
- University of North Carolina Nutrition Research Institute
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Experimental
Experimental
Placebo
Palmitoleic acid, 500 mg (Dose 1)
Palmitoleic acid, 1,000 mg (Dose 2)
The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.